Merck & Co. Launches AI Drug Discovery Partnership Targeting IBD, Atopic Dermatitis, Multiple Sclerosis
Merck & Co. announced a strategic collaboration with Mayo Clinic to leverage artificial intelligence and advanced analytics using Mayo Clinic’s multimodal data for AI model validation and drug development. The partnership will target inflammatory bowel disease, atopic dermatitis and multiple sclerosis to accelerate tailored therapy discovery.
1. Partnership Overview
Merck & Co. has entered a strategic collaboration with Mayo Clinic to harness artificial intelligence and advanced analytics in drug discovery. This marks Mayo Clinic’s first partnership of this scale with a global biopharmaceutical company.
2. AI and Data Utilization
Under the agreement, Merck will access and leverage multimodal data sets from Mayo Clinic, including laboratory results, imaging and clinical insights, to validate AI models and refine drug development strategies.
3. Targeted Therapeutic Focus
The initial phase of the collaboration will concentrate on high-need areas such as inflammatory bowel disease, atopic dermatitis and multiple sclerosis, aiming to accelerate the discovery of more effective, tailored therapies.